A Phase I Open Label Study Of Panobinostat In Combination With Lenalidomide, Bortezomib, And Dexamethasone In Patients With Relapsed And Relapsed/Refractory Multiple Myeloma
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 15 Feb 2018
At a glance
- Drugs Panobinostat (Primary) ; Bortezomib; Dexamethasone; Lenalidomide
- Indications Multiple myeloma
- Focus Adverse reactions
- Acronyms PanRVD
- 09 Feb 2018 Planned primary completion date changed from 1 Dec 2017 to 1 Jun 2018.
- 24 Jan 2017 Planned primary completion date changed from 1 Dec 2016 to 1 Dec 2017.
- 24 Jan 2017 Status changed from recruiting to active, no longer recruiting.